Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol

[1]  K. Otani,et al.  Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene , 2000, Psychopharmacology.

[2]  S. Ulrich,et al.  Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. , 1999, International clinical psychopharmacology.

[3]  K. Otani,et al.  Effects of the CYP2D6*10 allele on the steady‐state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia , 1999, Clinical pharmacology and therapeutics.

[4]  R. Petty.  Prolactin and antipsychotic medications: mechanism of action , 1999, Schizophrenia Research.

[5]  L. Farde,et al.  Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. , 1998, Journal of clinical psychopharmacology.

[6]  K. Otani,et al.  Prolactin response to bromperidol treatment in schizophrenic patients. , 1998, Pharmacology & toxicology.

[7]  K. Otani,et al.  Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. , 1997, Pharmacogenetics.

[8]  L. Bertilsson,et al.  Polymorphic Drug Oxidation , 1996 .

[9]  O. Andreassen,et al.  Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. , 1995, Pharmacogenetics.

[10]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[11]  M. W. Tsang,et al.  Metabolism of haloperidol: clinical implications and unanswered questions. , 1994, Journal of clinical psychopharmacology.

[12]  K. Otani,et al.  Prolactin response to zotepine in schizophrenic patients , 1993 .

[13]  L. Bertilsson,et al.  Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. , 1992, Therapeutic drug monitoring.

[14]  C. Alm,et al.  Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. , 1992, Therapeutic drug monitoring.

[15]  S. Marder,et al.  Serum prolactin as a correlate of clinical response to haloperidol. , 1991, Journal of clinical psychopharmacology.

[16]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[17]  W. Bowen,et al.  Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. , 1990, European journal of pharmacology.

[18]  Y. Ohkura,et al.  Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. , 1989, Journal of chromatography.

[19]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[20]  P. Jatlow,et al.  Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. , 1984, The American journal of psychiatry.

[21]  R. Lu,et al.  Prolactin response to single and multiple doses of haloperidol in schizophrenic patients , 1984, Psychiatry Research.

[22]  R. Rubin,et al.  Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level. , 1980, Archives of general psychiatry.